GVP Module VII Explained: The EU PSUR

Introduction

The periodic safety update report (PSUR) is a structured post-authorisation pharmacovigilance report used to provide a periodic evaluation of the safety profile and benefit-risk balance of a medicinal product or active substance. In the European Union, the PSUR is not simply a chronological compilation of adverse reaction cases. It is part of the regulatory system for periodically reassessing whether new safety information changes the known risks, benefits, or overall benefit-risk balance of a medicine.

GVP Module VII establishes the EU framework for PSUR content, preparation, submission and assessment. The current EMA GVP page identifies Module VII as Rev. 1, with legal effect from 13 December 2013. EMA also maintains additional explanatory and procedural guidance, particularly for the EU single-assessment process. citeturn1search0turn0search0

The practical importance of Module VII is therefore broader than writing a report. A compliant PSUR process requires the MAH to identify the correct reporting obligation, establish the appropriate data lock point, collect and evaluate relevant safety and benefit information, integrate the evidence into a benefit-risk assessment, reach defensible conclusions and submit the report through the applicable EU procedure.

1. Where Module VII Fits in the EU Pharmacovigilance System

PSURs sit within the post-authorisation safety surveillance system alongside individual case safety reports, signal management, risk management plans, post-authorisation safety studies and regulatory safety actions.

The relationship can be represented as:

Individual cases ─┐
                  │
Signal management ├──→ Safety evaluation ──→ PSUR
                  │                         │
Literature ──────┤                         ↓
Studies ─────────┤                  Benefit-risk evaluation
                  │                         │
RMP / risks ─────┘                         ↓
                                      Regulatory action

The PSUR does not replace these processes. It integrates information generated through them and provides a periodic structured assessment.

This distinction is important. A PSUR may identify a safety concern, but the underlying signal-management process remains a separate pharmacovigilance activity. Similarly, an RMP describes the risk-management system and planned activities; the PSUR evaluates new information and can lead to conclusions that require an RMP update.

2. What the PSUR Is Intended to Achieve

The fundamental purpose of the PSUR is periodic assessment of the benefit-risk balance. EMA describes PSURs as reports that provide an evaluation of the benefit-risk balance of a medicine and explains that the information is used to determine whether new risks have emerged or whether the benefit-risk balance has changed and whether further investigation or regulatory action is required. citeturn0search4turn0search7

This means that a PSUR should answer questions such as:

• What new safety information became available during the reporting interval?
• How does that information affect existing safety concerns?
• Are there newly identified risks?
• Has the frequency, severity or characterisation of a known risk changed?
• Is there new information about missing information?
• Has new evidence changed understanding of the medicine's benefits?
• Does the integrated evidence change the benefit-risk balance?
• Are additional pharmacovigilance or regulatory actions necessary?

A PSUR that merely reproduces tables without evaluating their significance does not fulfil this purpose.

3. The PSUR Is an Evaluation, Not a Data Dump

The distinction between data presentation and evaluation is central to good PSUR practice.

For example, a PSUR may contain an increase in reports of an adverse event. The important question is not simply whether the number increased. The assessment should consider relevant exposure, reporting patterns, reporting bias, seriousness, clinical plausibility, temporal relationship, alternative explanations, background incidence where available, literature and other evidence.

Likewise, absence of reports does not necessarily demonstrate absence of risk. Changes in reporting behaviour, exposure, indication, awareness, stimulated reporting and database completeness may influence the observed data.

The PSUR therefore requires interpretation of evidence in its clinical and epidemiological context.

4. The PSUR Lifecycle

A robust PSUR process can be viewed as a controlled lifecycle:

Determine obligation
        ↓
Identify EURD / reporting schedule
        ↓
Define DLP and reporting interval
        ↓
Establish data sources and responsibilities
        ↓
Collect and reconcile information
        ↓
Analyse safety information
        ↓
Evaluate benefits
        ↓
Perform integrated benefit-risk analysis
        ↓
Define conclusions and actions
        ↓
Quality review / governance
        ↓
Submit through applicable EU procedure
        ↓
Respond to assessment / regulatory follow-up
        ↓
Feed outcomes into PV system and RMP

Each stage has its own controls. A scientifically strong report can still fail operationally if the wrong reporting period or submission obligation is used.

5. Who Is Responsible?

The marketing authorisation holder is responsible for preparing and submitting the PSUR in accordance with applicable requirements. The work may involve a cross-functional team including pharmacovigilance, epidemiology, clinical development, medical affairs, regulatory affairs, statistics, safety science and other subject-matter experts.

Outsourcing parts of PSUR preparation does not remove the MAH's responsibility for the quality and regulatory appropriateness of the final report.

The QPPV's role should be understood in the context of overall pharmacovigilance oversight. The QPPV does not necessarily author every section, but the PV system should provide appropriate governance and escalation so that significant safety issues identified through PSUR preparation are recognised and managed.

6. Module VII and the EU Regulatory Network

Module VII contains both PSUR content requirements and EU-specific procedural provisions. These include the EU reference-date system, submission schedules and the processes used to assess PSURs across different authorisation situations. citeturn1search21

The EU Reference Dates (EURD) list is particularly important. EMA states that MAHs must submit PSURs according to the dates published in the EURD list, and the current list is periodically updated. The EURD list is therefore not merely an informational calendar. It is a central regulatory control for PSUR planning. citeturn0search1turn0search26

7. PSUR and PSUSA

PSUR single assessment (PSUSA) is the EU process through which PSURs for medicines containing the same active substance or combination can be assessed together, including products subject to different marketing authorisations and authorisation routes.

EMA explains that PSUSA aims to harmonise and strengthen the benefit-risk review across the European Economic Area. The assessment may result in PRAC recommendations and, depending on the authorisation circumstances, corresponding EU regulatory outcomes. citeturn0search0turn0search4

The distinction between the PSUR document and the PSUSA procedure should be maintained throughout the QPPV.com series. The PSUR is the MAH's report. PSUSA is an EU assessment procedure involving the relevant regulatory network.

8. PSUR Submission Infrastructure

The EU PSUR Repository is the central platform for PSUR submissions and related documents. EMA states that its use has been mandatory since 13 June 2016 for applicable EU PSUR submissions, and the repository supports both PSUSA procedures and relevant procedures outside the EURD list. citeturn0search2turn0search6

Current EMA eSubmission information also specifies technical submission requirements. For example, the PSUR repository currently states that PSURs must be submitted in eCTD format and that other electronic formats may lead to rejection. Technical requirements should therefore be checked at the time of submission rather than assumed from historical procedures. citeturn0search3

9. Why Module VII Requires Careful Maintenance

PSUR requirements sit at the intersection of legislation, GVP guidance, EURD decisions, procedural guidance and technical submission requirements.

EMA currently notes that the Module VII explanatory note and PSUSA assessor Q&A provide additional clarification for certain aspects of single assessment involving nationally authorised products and should be considered interim guidance until Module VII is revised. citeturn1search4

This is an important lesson for anyone using the PSUR series: the article should identify the regulatory version and relevant supporting guidance rather than treating the Module VII text as an isolated, permanently complete document.

10. Common Conceptual Errors

Several recurring misunderstandings should be avoided.

PSUR is not the same as an ICSR review

ICSR processing determines how individual reports are collected, assessed and submitted. The PSUR evaluates the accumulated evidence and its implications for the medicine's safety and benefit-risk balance.

PSUR is not the same as a signal

A signal is information suggesting a new potentially causal association or a new aspect of a known association that warrants further investigation. A PSUR is a periodic regulatory evaluation containing information from multiple sources and activities.

PSUR is not the same as an RMP

The RMP describes the risk-management system, including identified and potential risks, missing information and planned pharmacovigilance and risk-minimisation activities. The PSUR periodically evaluates new evidence and can trigger changes to that system.

PSUR is not simply an annual report

Submission frequency is determined by the applicable regulatory framework and, for substances on the EURD list, the applicable EURD entry. The timing cannot safely be inferred from a generic annual calendar. citeturn0search1turn0search23

11. What the Rest of the PSUR Series Will Cover

The following articles will progressively address:

• scope and regulatory purpose;
• data lock points, reporting intervals and timelines;
• reference data and international safety information;
• safety evaluation;
• benefit evaluation;
• integrated benefit-risk analysis;
• actions taken and regulatory implications;
• multiple products, substances and MAHs;
• PSUSA;
• assessment and PRAC follow-up;
• PSUR quality systems and inspection readiness;
• and common PSUR deficiencies.

This pillar article therefore establishes the architecture rather than attempting to reproduce every operational detail in Module VII.

Key Takeaways

• The EU PSUR is a periodic regulatory evaluation of safety information and the benefit-risk balance.
• Module VII covers both report content and important EU procedural requirements.
• The PSUR is an evaluation, not a compilation of raw safety data.
• PSUR preparation depends on accurate identification of the applicable reporting obligation, DLP and submission timetable.
• The EURD list is a critical regulatory planning instrument.
• PSUR and PSUSA are related but distinct: the former is the report, the latter is an EU assessment procedure.
• PSUR conclusions can have consequences for the RMP, pharmacovigilance activities, risk minimisation and regulatory action.
• The PSUR Repository is the central EU submission platform for applicable PSURs.
• Current procedural and technical guidance must be checked because supporting requirements can change even when the core Module VII text remains unchanged.

References

1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module VII — Periodic safety update report (Rev. 1), EMA/816292/2011 Rev. 1.
2. European Medicines Agency. Periodic safety update reports (PSURs) — explanatory note and PSUSA guidance.
3. European Medicines Agency. List of European Union reference dates and frequency of submission of PSURs (EURD list).
4. European Medicines Agency. PSUR Repository and eSubmission guidance.
5. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. Directive 2001/83/EC of the European Parliament and of the Council, as amended.

Regulatory Note

This article is an educational explanation of the EU PSUR framework based on current EMA GVP and associated EU regulatory guidance. It does not replace the applicable legislation, GVP Module VII, the current EURD list, EMA procedural guidance, PSUR Repository technical requirements or an organisation's controlled procedures.

Because PSUR requirements depend on current regulatory schedules, EURD entries, procedural guidance and technical submission requirements, users should verify the current source documents before preparing or submitting a PSUR.

19. The PSUR Is a Periodic Safety Evaluation

The PSUR should not be understood as a chronological dump of individual case reports.

Its regulatory purpose is to provide a structured periodic evaluation of the safety profile of a medicinal product or active substance, taking into account relevant new information and the cumulative knowledge available during the reporting interval.

This distinction affects how the report is prepared. The author must move from data to interpretation:

New safety information
        ↓
Data validation and analysis
        ↓
Clinical interpretation
        ↓
Cumulative assessment
        ↓
Benefit-risk conclusion
        ↓
Regulatory action, where appropriate

A PSUR can therefore be data-rich without being analytically useful. The important question is not simply whether information was collected, but whether the report explains what that information means for the benefit-risk balance.

20. The Reporting Interval

The PSUR reporting interval defines the period for which new information is systematically evaluated.

The reporting period should not be confused with the entire history of the product. The PSUR combines information generated during the interval with relevant cumulative information needed to interpret the current safety profile.

The applicable frequency and submission dates depend on the regulatory situation and, where applicable, the European Union reference date (EURD) list and associated regulatory arrangements.

The organisation should therefore establish the applicable schedule from the current regulatory source rather than relying on an old internal calendar.

21. Data Lock Point

The data lock point (DLP) is the point at which the data set for the PSUR is closed for the defined reporting interval.

The DLP is operationally important because it creates a controlled boundary between the information systematically included in the report and information that becomes available afterwards.

A robust process should establish:

• the applicable DLP;
• the data sources required before closure;
• responsibilities for confirming data completeness;
• procedures for late-arriving information;
• and controls ensuring that the report is based on the intended data set.

The DLP should be treated as a controlled milestone, not simply a date printed on the cover page.

22. What Information Enters a PSUR?

The PSUR draws upon multiple relevant sources of safety information.

Depending on the product and regulatory context, these can include:

• individual case safety reports;
• clinical studies;
• non-interventional studies;
• literature;
• signal-management activities;
• exposure information;
• regulatory actions and requests;
• information from other data sources;
• and new efficacy or effectiveness information where relevant to benefit-risk assessment.

The exact information requirements should be determined from the current Module VII structure and applicable regulatory guidance.

The key principle is integration. A PSUR should not treat each data source as an isolated appendix when the information needs to be interpreted together.

23. The Relationship Between ICSRs and the PSUR

ICSRs are an important source of post-authorisation safety information, but the PSUR is not simply an aggregate ICSR report.

Individual cases provide evidence about reported suspected adverse reactions. The PSUR evaluates patterns and significance in the context of the overall safety profile.

For example, an increase in reports of a particular event may require consideration of:

• reporting volume and exposure;
• seriousness and clinical characteristics;
• reporting trends;
• possible reporting stimulation;
• literature evidence;
• clinical-study information;
• alternative explanations;
• and whether the pattern represents a new or changing safety concern.

This is why the PSUR and signal-management processes are closely related but not interchangeable.

24. The Relationship Between the PSUR and Signal Management

Signal management is a continuous pharmacovigilance process. The PSUR is a periodic regulatory assessment.

A signal identified during the reporting interval may therefore become an important component of the PSUR's safety evaluation. Conversely, the integrated analysis performed for a PSUR may identify a safety issue requiring further signal evaluation.

The relationship can be represented as:

Continuous PV surveillance
        ↓
Signal detection / evaluation
        ↓
New evidence
        ↓
Periodic PSUR assessment
        ↓
Benefit-risk conclusion
        ↓
Further PV / regulatory action

The existence of a PSUR does not replace the organisation's ongoing signal-management responsibilities.

25. The Relationship Between the PSUR and the RMP

The PSUR and Risk Management Plan (RMP) answer different questions.

The PSUR asks, broadly, what has been learned about the safety profile during the reporting cycle and what that means for benefit-risk.

The RMP describes the risk-management strategy and the pharmacovigilance and risk-minimisation activities designed to address identified uncertainties and risks.

New information from the PSUR may therefore have consequences for the RMP. Examples include:

• a newly identified important risk;
• a change in the understanding of an existing risk;
• new missing information;
• a need for additional pharmacovigilance activity;
• or a change in risk-minimisation measures.

The PSUR should not automatically reproduce the RMP. Instead, the two documents should remain coherent and mutually consistent.

26. Multiple Products and Active Substances

EU PSUR preparation can involve products with the same active substance, multiple marketing authorisation holders, different formulations or different indications.

The applicable regulatory procedure determines how these situations are handled.

A major operational risk is fragmentation: different organisations may hold different parts of the safety evidence while the regulatory assessment requires an integrated view.

Governance should therefore establish clear responsibility for data exchange, common reference information, reconciliation and review of the final safety assessment.

27. The PSUR and the European Union Reference Date

The EURD list is a central operational element for substances subject to the EU periodic reporting system.

For an applicable substance, the organisation should verify the current EURD entry rather than assuming that an historical reporting schedule remains correct.

Relevant attributes can include the EU reference date, frequency and associated submission information.

A controlled process should record the source used to establish the reporting schedule and should monitor changes to the EURD list.

28. PSUSA

The Periodic Safety Update Report Single Assessment (PSUSA) is the EU regulatory procedure through which periodic safety information can be assessed for the relevant products and active substances within the applicable regulatory framework.

The PSUR is the submitted safety document; the PSUSA is the regulatory assessment procedure.

This distinction is important because the preparation of a high-quality PSUR and the subsequent regulatory assessment are related but different activities.

A PSUR should therefore be prepared so that its reasoning and evidence can withstand regulatory assessment rather than being written merely to satisfy a document-submission milestone.

29. The PSUR Repository

The PSUR Repository provides the EU regulatory infrastructure for submission and management of PSUR-related documents in the applicable procedures.

Operational teams should distinguish the scientific content of the PSUR from the technical mechanics of submission.

Submission controls should nevertheless be integrated into the quality system because a scientifically adequate report can still create a compliance problem if it is submitted incorrectly, to the wrong procedure, or after the applicable deadline.

30. Who Owns the PSUR?

Preparation commonly involves multiple functions and data owners.

Depending on the organisation, contributors may include:

• pharmacovigilance case management;
• signal management;
• medical safety;
• epidemiology or pharmacoepidemiology;
• clinical development;
• regulatory affairs;
• benefit-risk specialists;
• statistics or data science;
• and subject-matter experts.

The QPPV should have appropriate oversight of the process and the quality of the resulting pharmacovigilance assessment.

Responsibility should not become fragmented simply because the evidence comes from different departments.

31. The PSUR as an Evidence-Integration Exercise

A strong PSUR connects apparently separate observations.

For example:

ICSR trend
   +
literature evidence
   +
clinical-study findings
   +
exposure estimate
   +
known biological plausibility
   +
previous regulatory assessment
        ↓
Integrated safety interpretation

The report should explain whether the combined evidence changes the understanding of the safety profile.

Simply placing five data summaries next to each other does not necessarily constitute an integrated assessment.

32. Common Conceptual Errors

Treating the PSUR as an ICSR dump

A list of cases without interpretation does not fulfil the analytical purpose of periodic safety evaluation.

Treating every new report as a new signal

Individual cases contribute to the evidence base but do not automatically constitute validated signals.

Treating the PSUR as an RMP update

The PSUR evaluates accumulated evidence; the RMP describes risk-management strategy. They should interact without becoming the same document.

Treating the DLP as the only important date

The DLP is one controlled milestone within a larger reporting and submission process.

Using an old EURD schedule

Regulatory schedules should be verified against the current applicable source.

33. What Makes a PSUR Authoritatively Useful?

A useful PSUR should allow a reviewer to understand:

1. what information became available;
2. how complete and reliable the information is;
3. what the clinically important findings are;
4. whether the evidence changes existing safety knowledge;
5. how the evidence affects benefit-risk;
6. whether additional action is required;
7. and whether the conclusions are supported by the underlying evidence.

This is the distinction between data aggregation and safety evaluation.

34. Inspection Perspective

An inspection can examine not only the final PSUR but the system that produced it.

Evidence may include:

• PSUR procedures and responsibilities;
• reporting-calendar controls;
• EURD monitoring;
• data-reconciliation records;
• source-data traceability;
• medical review;
• QC documentation;
• author/reviewer qualification;
• governance minutes;
• changes made during preparation;
• and evidence supporting the final conclusions.

An organisation should be able to reconstruct why a conclusion was reached, not merely produce a PDF of the final report.

Key Takeaways

• The PSUR is a periodic scientific evaluation, not a chronological compilation of cases.
• The DLP creates a controlled boundary for the reporting data set.
• The PSUR integrates multiple safety-information sources.
• ICSR data are important but do not by themselves constitute the PSUR safety evaluation.
• Signal management and PSUR preparation are complementary processes.
• PSUR conclusions can have implications for the RMP and other PV activities.
• The current EURD list should be used to establish applicable EU periodic-reporting schedules where relevant.
• PSUR and PSUSA are related but distinct: one is the report and the other is the regulatory assessment procedure.
• Submission infrastructure is part of operational compliance but does not replace scientific assessment.
• The PSUR should demonstrate integrated reasoning from evidence to benefit-risk conclusion.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic Safety Update Report.
2. European Medicines Agency. Good Pharmacovigilance Practices (GVP), current GVP index and revision information.
3. European Medicines Agency. European Union reference dates (EURD) list and frequency of submission of PSURs.
4. European Medicines Agency. PSUR Repository and related submission guidance.
5. European Medicines Agency. Periodic Safety Update Report Single Assessment (PSUSA) procedural guidance.
6. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
7. European Parliament and Council. Directive 2001/83/EC, as amended.

Regulatory Note

This article is an educational explanation of the EU PSUR framework. It does not replace current GVP Module VII, applicable EU legislation, the current EURD list, EMA procedural guidance, PSUR Repository technical requirements, or an organisation's approved procedures.

PSUR requirements and supporting procedures can change. Before preparing or submitting a PSUR, the applicable current regulatory documents, reporting schedule, procedure and technical submission requirements should be verified.

The article distinguishes regulatory requirements from practical interpretation. Examples are illustrative and are not presented as actual regulatory cases unless a specific authoritative source is identified.

35. A Controlled PSUR Preparation Workflow

A robust PSUR process should operate as a controlled project rather than as a writing exercise.

A practical sequence is:

Confirm regulatory schedule
        ↓
Confirm scope and products
        ↓
Establish DLP
        ↓
Issue data requests
        ↓
Reconcile source data
        ↓
Perform medical and scientific analysis
        ↓
Draft sections
        ↓
Cross-functional review
        ↓
Quality control
        ↓
Final benefit-risk assessment
        ↓
Approval
        ↓
Submission
        ↓
Regulatory follow-up

The detailed operational sequence should be defined in the organisation's controlled procedures and adapted to the applicable procedure.

36. Data Requests and Completeness

A PSUR is only as reliable as the evidence entering it.

Data requests should therefore identify the relevant sources, owners, reporting periods and expected delivery dates. Late or incomplete inputs should be visible rather than silently omitted.

Useful controls include:

• source inventory;
• named data owners;
• request and receipt dates;
• completeness checks;
• reconciliation against independent sources where appropriate;
• escalation of missing data;
• and documented treatment of information received after agreed milestones.

A completed table with a missing data source is not evidence of completeness.

37. Medical Review and Scientific Interpretation

The PSUR requires scientific judgement.

Medical review should consider whether quantitative patterns are clinically meaningful and whether apparently unrelated observations may represent a coherent safety concern.

Important questions can include:

• Is the observed pattern plausible?
• Is the increase explained by exposure or reporting behaviour?
• Are there important confounders?
• Does the evidence alter the known risk profile?
• Is additional investigation warranted?

The answer should be supported by the available evidence rather than by a predetermined conclusion.

38. Benefit-Risk Evaluation

The benefit-risk evaluation is the point at which safety information is considered in relation to therapeutic benefit.

A safety finding does not automatically mean that the overall benefit-risk balance has become unfavourable.

Conversely, a serious emerging concern should not be dismissed merely because the medicine continues to provide substantial therapeutic benefit.

A sound evaluation should explain:

1. what changed;
2. how certain the evidence is;
3. what the clinical consequences may be;
4. how the finding relates to benefits and existing risks;
5. and whether action is justified.

39. Regulatory Actions Taken During the Interval

The reporting interval may contain regulatory actions relevant to the safety profile.

These can affect the interpretation of subsequent data and may include changes to product information, restrictions, safety communications, additional studies or other regulatory measures.

The PSUR process should therefore have an effective interface with Regulatory Affairs and other functions responsible for regulatory intelligence.

40. Literature in the PSUR

Literature findings can contribute to the PSUR safety evaluation, but literature monitoring is a separate operational process.

The PSUR should use relevant literature evidence to support the safety assessment without reproducing the entire literature-monitoring workflow.

Where a published report constitutes an ICSR, the underlying case should also remain controlled within the ICSR process.

This illustrates an important principle across the GVP series: one source of information may participate in several PV processes, but each process has a distinct purpose.

41. Exposure Data

Interpretation of reporting frequency requires appropriate context about exposure.

Depending on the product and available information, exposure may be estimated using sales, prescriptions, patient-years, treatment courses or other appropriate measures.

Exposure estimates have limitations. They should therefore be described sufficiently for the reader to understand what they represent and what uncertainty remains.

An apparent increase in reports cannot be interpreted correctly if the underlying treated population has also changed substantially.

42. Cumulative Knowledge

The PSUR is periodic, but its conclusions are informed by cumulative knowledge.

The author should therefore distinguish:

• information that is new during the interval;
• information already known from previous reporting periods;
• and new interpretation arising from combining the two.

This distinction helps prevent both overstatement of novelty and failure to recognise a developing trend.

43. Quality Control

PSUR QC should test more than spelling and formatting.

Depending on the organisation's procedures, QC can examine:

• numerical accuracy;
• consistency between sections;
• source-data traceability;
• tables and figures;
• terminology;
• dates and reporting periods;
• consistency with the current product information;
• consistency with the RMP;
• consistency with signal-management conclusions;
• benefit-risk reasoning;
• and references.

A particularly valuable control is independent review of the major conclusions against the underlying evidence.

44. Traceability

A reviewer should be able to move from an important statement in the PSUR back to its supporting evidence.

For example:

Conclusion
   ↓
Analysis
   ↓
Table / figure
   ↓
Data source
   ↓
Controlled underlying record

The required level of traceability depends on the information and the organisation's procedures, but important regulatory conclusions should not depend on undocumented analysis.

45. Difficult Scenario: New Information After the DLP

Information may become available after the DLP but before submission.

The organisation should follow the applicable current guidance and its controlled procedure to determine whether and how the information should be incorporated, communicated or handled separately.

The important point is that the decision should be controlled and documented rather than made informally by an individual author.

46. Difficult Scenario: Conflicting Data Sources

Suppose the case database, literature review and clinical-study database suggest different frequencies or patterns.

The correct response is not to select whichever number produces the most convenient conclusion.

The discrepancy should be investigated, its causes documented and the limitations reflected in the scientific interpretation.

47. Difficult Scenario: Apparent Safety Increase With Increased Exposure

A substantial increase in adverse-event reports may occur at the same time as a substantial increase in exposure.

The interpretation therefore requires consideration of reporting rates, exposure estimates and other relevant evidence rather than relying on absolute report counts.

The PSUR should explain the interpretation sufficiently for the reviewer to understand why the conclusion was reached.

48. Difficult Scenario: Important Risk Without a New Signal

A risk may remain important even when no new signal is detected during the reporting interval.

Absence of a new signal is not evidence that an established risk has disappeared.

The PSUR should therefore consider the continuing evidence and whether the existing risk-management approach remains appropriate.

49. Difficult Scenario: PSUR and RMP Are Inconsistent

If the PSUR identifies a materially changed safety understanding while the RMP remains unchanged, the organisation should assess whether an RMP update or other regulatory action is warranted.

The correct response is not to modify one document merely to make the two documents look identical. The underlying scientific and regulatory reasoning must be reconciled first.

50. Difficult Scenario: Multiple MAHs

Where multiple MAHs contribute to a common safety assessment, governance becomes particularly important.

The process should define:

• data exchange;
• responsibilities;
• confidentiality arrangements;
• review and approval;
• handling of disagreements;
• and communication with the relevant regulatory procedure.

The final assessment should represent the evidence appropriately rather than simply combining independently written narratives.

51. Inspection Questions

An inspector may ask:

• How was the reporting schedule established?
• Who confirmed the DLP?
• How was data completeness demonstrated?
• How were late data handled?
• How were safety signals incorporated?
• How were conclusions medically reviewed?
• What evidence supports the benefit-risk conclusion?
• How does the PSUR relate to the current RMP?
• How were inconsistencies identified and resolved?
• How was QC performed?
• Can major conclusions be traced to source data?
• How were previous PSUR commitments or regulatory requests addressed?

The strongest answers are supported by controlled records rather than retrospective explanations.

52. Common PSUR Process Failures

Recurring process weaknesses can include:

• incorrect reporting schedules;
• incomplete data collection;
• poorly controlled DLPs;
• inadequate exposure estimates;
• unexplained numerical discrepancies;
• weak benefit-risk reasoning;
• failure to integrate signal information;
• inconsistent conclusions across sections;
• inadequate QC;
• insufficient traceability;
• and ineffective governance across contributors.

These should be treated as potential deficiency patterns, not as assertions that every item constitutes a formal regulatory finding.

53. QPPV Oversight

QPPV oversight should focus on whether the PSUR process provides a reliable assessment of the product's safety profile.

Useful questions include:

1. Is the reporting schedule controlled?
2. Is the data set demonstrably complete?
3. Are important signals reflected appropriately?
4. Are safety conclusions clinically credible?
5. Is benefit-risk reasoning adequately supported?
6. Are the PSUR and RMP coherent?
7. Are previous regulatory actions and commitments addressed?
8. Are significant disagreements escalated?
9. Does QC identify meaningful errors?
10. Could the organisation reproduce the evidence supporting its principal conclusions?

The QPPV should not substitute personal review for the controlled system. Effective oversight means having sufficient visibility into the quality and reliability of that system.

54. Final Practical Checklist

Before submission, the PSUR team should be able to answer yes to the following questions:

• Is the applicable reporting schedule confirmed from the current source?
• Is the scope correct?
• Is the DLP controlled?
• Have required data sources been identified and reconciled?
• Have important new safety findings been evaluated?
• Have relevant cumulative data been considered?
• Are exposure estimates appropriate and qualified?
• Are signal-management findings integrated?
• Is the benefit-risk evaluation evidence-based?
• Are conclusions internally consistent?
• Is the relationship with the RMP understood?
• Has appropriate QC been completed?
• Can important conclusions be traced to supporting evidence?
• Are required approvals documented?
• Is submission technically and procedurally controlled?
• Are regulatory follow-up responsibilities assigned?

55. Key Takeaways

The EU PSUR is best understood as a controlled periodic safety-evaluation process, not simply as a report-writing task.

Its quality depends on the integrity of the reporting schedule, completeness of the data, quality of scientific interpretation, coherence of the benefit-risk evaluation and traceability of the evidence.

The PSUR also sits within a wider pharmacovigilance system. Its conclusions can interact with signal management, risk management, regulatory action and other safety activities.

For an inspection-ready organisation, the final document is only one part of the evidence. The organisation should also be able to demonstrate how the report was constructed, reviewed, challenged, approved and submitted.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic Safety Update Report.
2. European Medicines Agency. GVP Module I — Pharmacovigilance systems and quality systems.
3. European Medicines Agency. GVP Module V — Risk-management systems.
4. European Medicines Agency. GVP Module IX — Signal management.
5. European Medicines Agency. European Union reference dates (EURD) list and frequency of submission of PSURs.
6. European Medicines Agency. PSUR Repository and PSUSA procedural guidance.
7. European Commission. Commission Implementing Regulation (EU) No 520/2012, as amended.
8. European Parliament and Council. Directive 2001/83/EC, as amended.

Regulatory Note

This article is an educational interpretation of the EU PSUR framework and associated operational considerations. It does not replace current EU legislation, GVP Module VII, the current EURD list, EMA procedural guidance, PSUR Repository technical requirements, regulatory assessment instructions or an organisation's approved procedures.

Regulatory schedules, procedures and supporting guidance may change. Before preparing or submitting a PSUR, the current applicable requirements should be verified.

The inspection and difficult-case sections describe practical learning scenarios and potential deficiency patterns. They are not presented as quotations or as claims that each example represents a formally published regulatory inspection finding.